Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 6/20 | 0.68 |
| ▸ | APP | P05067 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | RAB9A | P51151 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 9/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817276 | 0.98 | ALDH1A3 (0.70) | ALDH1A3APPKDM4ERAB9ANPC1 | |
| SCHEMBL31380867 | 0.90 | ALDH1A3 (0.86) | ALDH1A3APPKDM4ERAB9ANPC1 | |
| SCHEMBL13325701 | 0.86 | ALDH1A3 (0.74) | ALDH1A3APPKDM4ERAB9ANPC1 | |
| Bromide SCHEMBL2901637 | 0.85 | ALDH1A3 (0.68) | ALDH1A3APPKDM4ERAB9ANPC1 | |
| SCHEMBL2906109 | 0.84 | ALDH1A3 (0.70) | ALDH1A3APPKDM4ERAB9ANPC1 | |
| SCHEMBL10527726 | 0.84 | ALDH1A3 (0.70) | ALDH1A3APPKDM4ERAB9ANPC1 | |
| SCHEMBL2899627 | 0.84 | ALDH1A3 (0.70) | ALDH1A3APPKDM4ERAB9ANPC1 | |
| SCHEMBL28338009 | 0.83 | ALDH1A3 (0.81) | ALDH1A3APPKDM4ERAB9ANPC1 | |
| SCHEMBL12903849 | 0.81 | APP (1.00) | ALDH1A3APPTLR9TLR7 | |
| SCHEMBL2257095 | 0.81 | APP (0.73) | ALDH1A3APPKDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042501-B1 | COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDIPHYSICS CO LTD (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-8277777-B2 | Compound having affinity for amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20100092387-A1 | Novel Compound Having Affinity For Amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2042501-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092387-A1 | Novel Compound Having Affinity For Amyloid | APP, SLC43A1, APBA1 | ALDH1A3 3784/4885APP 1/4885KDM4E 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.